SYSTEMATIC REVIEW

Candida antifungal drug resistance in sub-Saharan African populations: A systematic review [version 1; peer review: 2 approved]

Charlene Wilma Joyce Africa , Pedro Miguel dos Santos Abrantes

Microbial Endogenous Infections (MENIS) Research Laboratories, Department of Medical Biosciences, University of the Western Cape, Bellville, South Africa

V1 First published: 08 Dec 2016, 5:2832
<https://doi.org/10.12688/f1000research.10327.1>

Latest published: 20 Jan 2017, 5:2832
<https://doi.org/10.12688/f1000research.10327.2>

Abstract

Background: *Candida* infections are responsible for increased morbidity and mortality rates in at-risk patients, especially in developing countries where there is limited access to antifungal drugs and a high burden of HIV co-infection. **Objectives:** This study aimed to identify antifungal drug resistance patterns within the subcontinent of Africa. **Methods:** A literature search was conducted on published studies that employed antifungal susceptibility testing on clinical *Candida* isolates from sub-Saharan African countries using Pubmed and Google Scholar. **Results:** A total of 21 studies from 8 countries constituted this review. Only studies conducted in sub-Saharan Africa and employing antifungal drug susceptibility testing were included. Regional differences in *Candida* species prevalence and resistance patterns were identified. **Discussion:** The outcomes of this review highlight the need for a revision of antifungal therapy guidelines in regions most affected by *Candida* drug resistance. Better controls in antimicrobial drug distribution and the implementation of regional antimicrobial susceptibility surveillance programmes are required in order to reduce the high *Candida* drug resistance levels seen to be emerging in sub-Saharan Africa.

Keywords

Candida, antifungal drug resistance, Africa

Open Peer Review

Approval Status

	1	2
version 2 (revision) 20 Jan 2017		
version 1 08 Dec 2016	 view	 view
<p>1. António Paulo Gouveia de Almeida, Universidade NOVA de Lisboa, Lisbon, Portugal University of Pretoria, Pretoria, South Africa</p> <p>2. Roland N. Ndip, University of Buea, Buea, Cameroon</p> <p>Any reports and responses or comments on the article can be found at the end of the article.</p>		

Corresponding author: Charlene Wilma Joyce Africa (cafrica@uwc.ac.za)

Competing interests: No competing interests were disclosed.

Grant information: This study was supported by the Research Office of the University of the Western Cape (project registration no. ScRIRC2012/10/72).

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright: © 2016 Africa CWJ and Abrantes PMdS. This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Data associated with the article are available under the terms of the [Creative Commons Zero "No rights reserved" data waiver](#) (CC0 1.0 Public domain dedication).

How to cite this article: Africa CWJ and Abrantes PMdS. *Candida* antifungal drug resistance in sub-Saharan African populations: A systematic review [version 1; peer review: 2 approved] F1000Research 2016, 5:2832 <https://doi.org/10.12688/f1000research.10327.1>

First published: 08 Dec 2016, 5:2832 <https://doi.org/10.12688/f1000research.10327.1>

Introduction

Candida species are known to shift from commensal to opportunistic infectious agents when triggered by factors such as immunosuppression, continuous usage of antibiotics and poor nutrition, leading to increased patient morbidity and mortality¹⁻³. In severely immunocompromised patients, *Candida* species can spread through the bloodstream and gastrointestinal tract. This can lead to systemic candidiasis, with a reported mortality rate in developed countries of 38%⁴ and 44%⁵. *Candida* is currently the 4th most commonly isolated microorganism in nosocomial bloodstream infections⁶ and has been implicated in >78% of cancerous and precancerous oral lesions⁷.

Various antifungal drugs with different modes of action have been developed over the years. These include polyene antifungals (e.g. nystatin and amphotericin B), which interfere with ergosterol synthesis, thereby causing cell membrane leakage; the imidazoles (e.g. miconazole, clotrimazole, econazole and ketoconazole), which also interfere with ergosterol and other cell membrane sterol synthesis; the echinocandins (e.g. anidulafungin, micafungin and caspofungin), which inhibit β 1–3 glucan synthesis, affecting the fungal cell wall and 5-flucytosine that in turn interferes with fungal RNA and DNA synthesis⁸. The triazoles (including fluconazole, posaconazole, voriconazole and itraconazole) interfere with the synthesis of ergosterol and have been shown to have fewer side effects than some of the other antifungal drug classes⁹.

Resistance to available antifungal therapies is widespread^{10,11}, probably due to the widespread and repeated use of these drugs¹². Different *Candida* species have varying resistance patterns, which appear to be geographically determined^{13,14}. Therefore early recognition of resistance facilitates the selection of an appropriate antifungal drug, with the use of oral antifungals in oropharyngeal candidiasis reserved for cases where there is no response to topical antifungal treatment¹⁵. Resistance pattern surveillance to avoid an even higher number of improperly treated, and therefore resistant fungal infections, is imperative¹⁶. This is a cause for concern in the case of immunocompromised patients, who are at a much higher risk of developing opportunistic complications. Importantly, sub-Saharan Africa is the region most affected by HIV, with approximately 25.8 million infected people in 2014 and accounting for almost 70% of the global number of new HIV infections (<http://www.who.int/mediacentre/factsheets/fs360/en/>)⁹.

Programmes on species prevalence and antifungal surveillance have been successfully developed and introduced in Europe, Asia-Pacific, Latin America and North America¹⁷⁻¹⁹. The gap in antifungal drug resistance surveillance in Africa has been documented²⁰. Surveillance programmes are crucial tools in the transition from empirical antifungal treatment, which often does not work due to the diverse resistance levels seen in different regions, and the presence of species that are intrinsically resistant to certain antifungal drugs. The non-existence of routine diagnostics laboratories in most African countries has meant that many African patients are treated without the knowledge of which species they harbour and without any updated guideline data that could be used as a reference in prescribing antifungals. Possible causes for the lack of *Candida* surveillance programmes in Africa include lack of funding, the

limited number of research collaborations and the existence of conflict areas within the continent. This prompted the need for a review of the current situation in Africa regarding the drug susceptibility profiles of *Candida* species available from different regions.

Methods

Data collection

A literature search was conducted on 21 published studies that employed antifungal susceptibility testing on clinical *Candida* isolates from 8 sub-Saharan African countries, with the aim of identifying antifungal drug resistance patterns within different regions of the subcontinent and included resistance data for 14 antifungal drugs. Searches were performed on PubMed and Google Scholar between August and November 2016 using the keywords ‘*Candida*’, ‘Susceptibility Testing’, ‘Drug Resistance’ and ‘Antifungal’.

Data extracted from the individual studies included the regions within the different countries, patient health information, the methods used for antifungal susceptibility testing, the frequency of *Candida* species and their susceptibilities to antifungal drugs (Dataset 1²¹).

Inclusion criteria

Only studies conducted in sub-Saharan Africa between the years 1998 and 2016 employing antifungal drug susceptibility testing were included.

Exclusion criteria

Studies conducted in Africa which reported on the prevalence of *Candida* but did not describe antimicrobial susceptibility were excluded from this review.

Results

The study populations included healthy^{22,23}, HIV-positive²²⁻²³ and cancer patients²³, as well as patients with genitourinary tract infections³⁶⁻³⁹, respiratory tract infections^{32,39}, meningitis³⁹ and candidemia^{40,41}. Most studies relied on broth microdilution or disk diffusion for antimicrobial susceptibility testing, while one of the publications was a retrospective clinical study based on the patients’ response to antifungal therapy.

This review included seven studies from two regions in South Africa^{22-25,36,40,41}, three studies from different regions in Ethiopia³³⁻³⁵, three studies from two regions in Cameroon²⁵⁻²⁷, three studies from different regions in Nigeria^{28,29,37}, two studies from the same region in Ivory Coast^{30,38}, one study from Tanzania³¹, one study from Kenya³² and one study from Ghana³⁹. Due to the paucity of studies and differences in isolation and antifungal susceptibility testing, a meta-analysis could not be conducted.

Non-albicans species, such as *C. glabrata* and *C. krusei* are reported to have innate resistance to antifungal drugs. *C. krusei* resistance has been reported from South Africa^{22,25}, Cameroon²⁵, Nigeria^{28,37}, Ghana³⁹, Tanzania³¹ and Ethiopia³⁴. Initially thought to have innate resistance to azoles, *C. glabrata* resistance has been reported in Cameroon²⁵, Ethiopia³⁴ and Tanzania³¹, while susceptibility has been reported in South Africa^{22,25} and Nigeria²⁸. This discrepancy may be explained by the phenotypic similarity between *C. glabrata*, *C. nivariensis* and *C. bracarensis*, which could possibly be

confused in the absence of molecular typing methods and show different antifungal profiles⁴². Resistant *C. glabrata* has increased in patients presenting with candidiasis in recent years⁴³, with increased mortality rates⁴⁴, and echinocandins have been recommended for the treatment of invasive *C. glabrata* infections showing resistance to azoles. However, co-resistance to both echinocandins and azoles in clinical isolates of *C. glabrata* have been reported⁴⁵, with two cases of echinocandin-resistant *C. glabrata* infections recently reported from South Africa³⁶.

A new multi-drug resistant species, *C. auris* is taking the world by storm. First discovered in Japan⁴⁶, this species has been found in nine other countries on four continents. The Centre for Disease Control and Prevention (CDC) has issued a warning for increased awareness of *C. auris* in healthcare settings. This nosocomial pathogen is frequently misdiagnosed, shows resistance to different classes of antifungals routinely administered, and is associated with high mortality rates⁴⁷. The isolation of this species in South Africa⁴⁰ appears to be the only report in Africa at the time of writing this paper.

Regional differences in *Candida* susceptibility profiles have been observed. In South Africa, earlier reports of baseline data demonstrated a high susceptibility (100%) of *C. albicans* to fluconazole, along with intrinsically resistant non-albicans species^{22,24}, with more recent studies in South Africa showing an emerging resistance to azoles^{23,25,48}. The reasons for this change in susceptibility patterns is not clear, but it is worth noting that the earlier studies were done before the 2002 introduction of fluconazole as prophylaxis to patients attending HIV-AIDS clinics in South Africa⁴⁹.

Studies from abroad have reported cross-resistance to fluconazole in patients receiving itraconazole prophylaxis⁵⁰ and other previously administered azole therapies, such as ketoconazole and miconazole^{51,52}. Similar cross-resistance was recently reported in South Africa where 37% of *C. parapsilosis* isolates were susceptible to fluconazole and voriconazole, and 44% of fluconazole-resistant isolates were voriconazole cross-resistant⁴¹.

Studies from Bamenda²⁵ and Douala²⁶ in Cameroon showed high resistance of *C. albicans* isolates to azoles (>50% and 70% respectively), with low resistance reported from Mutengene²⁷ and Bamenda²⁵ for amphotericin B (4.9 and 4.3%) and 5-flucytosine (10.7 and 6.5%), respectively. The Douala study, on the other hand, reported increased *C. albicans* resistance to amphotericin B (52.6%) and 5-flucytosine (70%). A comparison of the Mutengene and Bamenda studies further revealed that *C. dubliniensis* and *C. tropicalis* susceptibilities differed between the two groups, with *C. dubliniensis* showing susceptibility to fluconazole and 100% resistance to amphotericin B in the Bamenda group, and increased resistance (66%) to fluconazole and no resistance to amphotericin B in the Mutengene group. *C. tropicalis* showed resistance to amphotericin B in the Bamenda group (50%) and only 4.3% resistance in the Mutengene group.

C. albicans resistance to amphotericin B has also been reported in Kenya (25.6%)³² and Ghana (23.4%)³⁹, while no resistance was seen in studies from Ivory Coast^{30,38} nor Nigeria²⁹. Intermediate resistance values observed for clotrimazole and amphotericin B

in studies from South West Cameroon, may indicate the need for administering higher doses to effectively treat these patients. This raises some concern, since both drugs are toxic at high concentrations and might have various side effects, such as the reduction of blood pressure caused by clotrimazole therapy⁵³.

The application of topical antifungals, such as econazole and nystatin, is recommended for the localized treatment of *Candida* infections. *Candida* isolates from the Ivory Coast showed good susceptibility to nystatin with an increasing resistance noted in Ethiopia (1.3–4.7%), Kenya (36%), Gauteng, South Africa (67%) and Mutengene, Cameroon (68%). Resistance to econazole was reported in South West Cameroon^{26,27}. Overall, *Candida* isolates from Eastern African countries demonstrated the lowest resistance levels, with the exception of Kenya where resistance values for clotrimazole (74%) and nystatin (35.6%) were high³². Systemic antifungals are usually reserved for patients who are unresponsive to topical treatment in cases such as these.

Dataset 1. Antifungal drug resistance of *Candida* species per region

<http://dx.doi.org/10.5256/f1000research.10327.d145319>

Discussion

Fluconazole is widely used in public health settings in the African continent and is used empirically in the treatment of systemic or localized *Candida* infections⁵⁴, as it is less toxic and regarded as more effective than imidazole antifungals, such as ketoconazole or amphotericin B, even though it is a teratogenic drug^{55,56}. Although still somewhat effective in other regions, the use of azoles as first line drugs for systemic infection should be revisited in certain areas of South and West Africa, due to their increasing inefficacy. Regular monitoring of *Candida* at a regional level could therefore be an important tool to aid in the prescription of antifungals based on the prevalent species and their susceptibilities to antifungal drugs in areas where routine microbiological laboratory testing is not available.

The sale of antimicrobial medications is largely unregulated in Africa and is exacerbated by the influx of fake and adulterated drugs with little or no active ingredients, often available both in pharmacies and on the streets. This problem is aggravated by practitioners who prescribe antimicrobial medications empirically based on clinical presentation, without prior knowledge of which microbial agent(s) are causing infections in their patients. These issues pose a serious public health threat, as they are largely responsible for more and more antimicrobial drugs being rendered ineffective in treating life-threatening infections. This is especially true in the case of the antifungal armamentarium, which is already very limited⁵⁷, especially in resource-poor settings. Limitations of this study include the paucity of available data from African regions, differences in sample sourcing, as well as techniques for isolation and susceptibility profiles from different regions, all of which complicate a comparison of outcomes of the cited studies.

The regional differences in antifungal drug susceptibility of *Candida* species, often seen within the same country, are an important finding that justifies the implementation of *Candida* species

prevalence and susceptibility testing programmes in the African continent, notably in at-risk population groups, such as HIV patients. With the emergence of inherently drug resistant non-albicans species, more studies on *Candida* prevalence and drug susceptibility are needed throughout sub-Saharan Africa. This is most critical in resource-poor areas where there is little or no information available, such as southern (with the exception of South Africa) and central African countries and countries bordering the Sahara.

We would like to conclude by adding that *Candida* identification to species level is rarely made in clinical settings in Africa, and patients are treated empirically based on their clinical symptoms. The introduction of routine antimicrobial susceptibility testing before initiation of therapy can be relatively expensive, but is certainly a long-term cost effective solution in preventing the progression of drug resistance. Changes in drug susceptibility over time serve as a reminder for the need to test clinical *Candida* isolates for sensitivity to antifungal drugs in the effort to improve patient care and reduce patient morbidity and mortality.

Data availability

Dataset 1: Antifungal drug resistance of *Candida* species per region. DOI, [10.5256/f1000research.10327.d145319](https://doi.org/10.5256/f1000research.10327.d145319)²¹

Author contributions

CA conceived the study and contributed to the writing of the manuscript. PA wrote the first draft of the manuscript. Both authors were involved in the revision of the draft manuscript and have agreed to the final content.

Competing interests

No competing interests were disclosed.

Grant information

This study was supported by the Research Office of the University of the Western Cape (project registration no. ScRIRC2012/10/72).

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

- Akpan A, Morgan R: **Oral candidiasis.** *Postgrad Med J.* 2002; **78**(922): 455–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Jabra-Rizk MA, Falkler WA Jr, Enwonwu CO, et al.: **Prevalence of yeast among children in Nigeria and the United States.** *Oral Microbiol Immunol.* 2001; **16**(6): 383–5.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Owotade FJ, Patel M, Ralephenya TR, et al.: **Oral *Candida* colonization in HIV-positive women: associated factors and changes following antiretroviral therapy.** *J Med Microbiol.* 2013; **62**(Pt 1): 126–32.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Gudlaugsson O, Gillespie S, Lee K, et al.: **Attributable mortality of nosocomial candidemia, revisited.** *Clin Infect Dis.* 2003; **37**(9): 1172–7.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Almirante B, Rodríguez D, Park BJ, et al.: **Epidemiology and predictors of mortality in cases of *Candida* bloodstream infection: results from population-based surveillance, Barcelona, Spain, from 2002 to 2003.** *J Clin Microbiol.* 2005; **43**(4): 1829–35.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Budhavari S: **What's new in diagnostics? Fungitell®: 1,3 beta-D Glucan assay.** *South Afr J Epidemiol Infect.* 2009; **24**(1): 37–8.
[Reference Source](#)
- Mohd Bakri M, Mohd Hussaini H, Rachel Holmes A, et al.: **Revisiting the association between candidal infection and carcinoma, particularly oral squamous cell carcinoma.** *J Oral Microbiol.* 2010; **2**: 5780.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Odds FC, Brown AJ, Gow NA: **Antifungal agents: mechanisms of action.** *Trends Microbiol.* 2003; **11**(6): 272–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Khan ZK, Jain P: **Antifungal agents and immunomodulators in systemic mycoses.** *Indian J Chest Dis Allied Sci.* 2000; **42**(4): 345–55.
[PubMed Abstract](#)
- Luque AG, Biasoli MS, Tosello ME, et al.: **Oral yeast carriage in HIV-infected and non-infected populations in Rosario, Argentina.** *Mycoses.* 2009; **52**(1): 53–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Manzano-Gayosso P, Méndez-Tovar LJ, Hernández-Hernández F, et al.: **[Antifungal resistance: an emerging problem in Mexico].** *Gac Med Mex.* 2008; **144**(1): 23–6.
[PubMed Abstract](#)
- Jia XM, Ma ZP, Jia Y, et al.: **RTA2, a novel gene involved in azole resistance in *Candida albicans*.** *Biochem Biophys Res Commun.* 2008; **373**(4): 631–6.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Pfaller MA, Jones RN, Doern GV, et al.: **International surveillance of bloodstream infections due to *Candida* species: frequency of occurrence and antifungal susceptibilities of isolates collected in 1997 in the United States, Canada, and South America for the SENTRY Program.** The SENTRY Participant Group. *J Clin Microbiol.* 1998; **36**(7): 1886–9.
[PubMed Abstract](#) | [Free Full Text](#)
- Falagas ME, Roussos N, Vardakas KZ: **Relative frequency of albicans and the various non-albicans *Candida* spp among candidemia isolates from inpatients in various parts of the world: a systematic review.** *Int J Infect Dis.* 2010; **14**(11): e954–66.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Powderly WG, Mayer KH, Perfect JR: **Diagnosis and treatment of oropharyngeal candidiasis in patients infected with HIV: a critical reassessment.** *AIDS Res Hum Retroviruses.* 1999; **15**(16): 1405–12.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Godoy P, Tiraboschi IN, Severo LC, et al.: **Species distribution and antifungal susceptibility profile of *Candida* spp. bloodstream isolates from Latin American hospitals.** *Mem Inst Oswaldo Cruz.* 2003; **98**(3): 401–5.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Adriaenssens N, Coenen S, Muller A, et al.: **European Surveillance of Antimicrobial Consumption (ESAC): outpatient systemic antimycotic and antifungal use in Europe.** *J Antimicrob Chemother.* 2010; **65**(4): 769–74.
[PubMed Abstract](#)
- Cuenca-Estrella M, Rodríguez-Tudela JL, Córdoba S, et al.: **[Regional laboratory network for surveillance of invasive fungal infections and antifungal susceptibility in Latin America].** *Rev Panam Salud Publica.* 2008; **23**(2): 129–34.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Pfaller MA, Moet GJ, Messer SA, et al.: **Geographic variations in species distribution and echinocandin and azole antifungal resistance rates among *Candida* bloodstream infection isolates: report from the SENTRY Antimicrobial Surveillance Program (2008 to 2009).** *J Clin Microbiol.* 2011; **49**(1): 396–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- The World Health Organization: **Antimicrobial resistance global report on surveillance.** WHO Press, Geneva, Switzerland. ISBN 978 92 4 156474 8. 2014.
[Reference Source](#)
- Wilma Joyce Africa C, Dos Santos Abrantes PM: **Dataset 1 in: *Candida* antifungal drug resistance in sub-Saharan African populations: A systematic review.** *F1000Research.* 2016.
[Data Source](#)
- Blighaut E, Messer S, Hollis RJ, et al.: **Antifungal susceptibility of South African oral yeast isolates from HIV/AIDS patients and healthy individuals.** *Diagn Microbiol Infect Dis.* 2002; **44**(2): 169–74.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Owotade FJ, Gulube Z, Ramla S, et al.: **Antifungal susceptibility of *Candida***

- albicans* isolated from the oral cavities of patients with HIV infection and cancer. *SADJ*. 2016; 71(1): 8–11.
[Reference Source](#)
24. Blignaut E, Botes ME, Nieman HL: **The treatment of oral candidiasis in a cohort of South African HIV/AIDS patients.** *SADJ*. 1999; 54(12): 605–8.
[PubMed Abstract](#)
 25. Dos Santos Abrantes PM, McArthur CP, Africa CW: **Multi-drug resistant oral *Candida* species isolated from HIV-positive patients in South Africa and Cameroon.** *Diagn Microbiol Infect Dis*. 2014; 79(2): 222–7.
[PubMed Abstract](#) | [Publisher Full Text](#)
 26. Njunda AL, Nsagha DS, Assob JCN, *et al.*: ***In vitro* antifungal susceptibility patterns of *Candida albicans* from HIV and AIDS patients attending the Nylon Health District Hospital in Douala, Cameroon.** *J Pub Health Afr*. 2012; 3(1): 4–7.
[Publisher Full Text](#)
 27. Njunda LA, Assob JCN, Nsagha SD, *et al.*: **Oral and urinary colonization of *Candida* species in HIV/AIDS patients in Cameroon.** *Basic Sci Med*. 2013; 2(1): 1–8.
[Reference Source](#)
 28. Enwuru CA, Ogunledun A, Idika N, *et al.*: **Fluconazole resistant opportunistic oro-pharyngeal *Candida* and non-*Candida* yeast-like isolates from HIV-infected patients attending ARV clinics in Lagos, Nigeria.** *Afr Health Sci*. 2008; 8(3): 142–8.
[PubMed Abstract](#) | [Free Full Text](#)
 29. Nweze EI, Ogbonnaya UL: **Oral *Candida* isolates among HIV-infected subjects in Nigeria.** *J Microbiol Immunol Infect*. 2011; 44(3): 172–7.
[PubMed Abstract](#) | [Publisher Full Text](#)
 30. Nébavi F, Arnavielhe S, Le Guennec R, *et al.*: **Oropharyngeal candidiasis in AIDS patients from Abidjan (Ivory Coast): antifungal susceptibilities and multilocus enzyme electrophoresis analysis of *Candida albicans* isolates.** *Pathol Biol (Paris)*. 1998; 46(5): 307–14.
[PubMed Abstract](#)
 31. Hamza OJ, Matee MI, Moshi MJ, *et al.*: **Species distribution and *in vitro* antifungal susceptibility of oral yeast isolates from Tanzanian HIV-infected patients with primary and recurrent oropharyngeal candidiasis.** *BMC Microbiol*. 2008; 8: 135.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 32. Bii CC, Ouko TT, Amukoye E, *et al.*: **Antifungal drug susceptibility of *Candida albicans*.** *East Afr Med J*. 2002; 79(3): 143–5.
[PubMed Abstract](#) | [Publisher Full Text](#)
 33. Wabe NT, Hussein J, Suleman S, *et al.*: ***In vitro* antifungal susceptibility of *Candida albicans* isolates from oral cavities of patients infected with human immunodeficiency virus in Ethiopia.** *J Exp Integr Med*. 2011; 1(4): 265–71.
[Publisher Full Text](#)
 34. Mulu A, Kassu A, Anagaw B, *et al.*: **Frequent detection of 'azole' resistant *Candida* species among late presenting AIDS patients in northwest Ethiopia.** *BMC Infect Dis*. 2013; 13: 82.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 35. Moges B, Bitew A, Shewaamare A: **Spectrum and the *in vitro* antifungal susceptibility pattern of yeast isolates in Ethiopian HIV patients with oropharyngeal candidiasis.** *Int J Microbiol*. 2016; 2016: 3037817.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 36. Naicker SD, Magobo RE, Zulu TG, *et al.*: **Two echinocandin-resistant *Candida glabrata* FKS mutants from South Africa.** *Med Mycol Case Rep*. 2016; 11: 24–6.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 37. Akortha EE, Nwaugo VO, Chikwe NO: **Antifungal resistance among *Candida* species from patients with genitourinary tract infection isolated in Benin City, Edo state, Nigeria.** *Afr J Microbiol Res*. 2009; 3(11): 694–9.
[Reference Source](#)
 38. Djohan V, Angora KE, Vanga-Bosson AH, *et al.*: **[*In vitro* susceptibility of vaginal *Candida albicans* to antifungal drugs in Abidjan (Ivory Coast)].** *J Mycol Med*. 2012; 22(2): 129–33.
[PubMed Abstract](#) | [Publisher Full Text](#)
 39. Feglo PK, Narkwa P: **Prevalence and antifungal susceptibility patterns of yeast isolates at the Komfo Anokye Teaching Hospital (KATH), Kumasi, Ghana.** *British Microbiol Res J*. 2012; 2(1): 10–22.
[Publisher Full Text](#)
 40. Magobo RE, Corcoran C, Seetharam S, *et al.*: ***Candida auris*: An emerging, azole-resistant pathogen causing candidemia in South Africa.** *IJID*. 2014; 21(S1): 215.
[Publisher Full Text](#)
 41. Govender NP, Patel J, Magobo RE, *et al.*: **Emergence of azole-resistant *Candida parapsilosis* causing bloodstream infection: results from laboratory-based sentinel surveillance in South Africa.** *J Antimicrob Chemother*. 2016; 71(7): 1994–2004.
[PubMed Abstract](#) | [Publisher Full Text](#)
 42. Lockhart SR, Messer SA, Gherna M, *et al.*: **Identification of *Candida nivariensis* and *Candida bracarensis* in a large global collection of *Candida glabrata* isolates: comparison to the literature.** *J Clin Microbiol*. 2009; 47(4): 1216–7.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 43. Vermitsky JP, Edlind TD: **Azole resistance in *Candida glabrata*: coordinate upregulation of multidrug transporters and evidence for a Pdr1-like transcription factor.** *Antimicrob Agents Chemother*. 2004; 48(10): 3773–81.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 44. Yoo JI, Choi CW, Lee KM, *et al.*: **Gene Expression and Identification Related to Fluconazole Resistance of *Candida glabrata* Strains.** *Osong Public Health Res Perspect*. 2010; 1(1): 36–41.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 45. Alexander BD, Johnson MD, Pfeiffer CD, *et al.*: **Increasing echinocandin resistance in *Candida glabrata*: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations.** *Clin Infect Dis*. 2013; 56(12): 1724–32.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 46. Satoh K, Makimura K, Hasumi Y, *et al.*: ***Candida auris* sp. nov., a novel ascomycetous yeast isolated from the external ear canal of an inpatient in a Japanese hospital.** *Microbiol Immunol*. 2009; 53(1): 41–4.
[PubMed Abstract](#) | [Publisher Full Text](#)
 47. Chowdhary A, Voss A, Meis JF: **Multidrug-resistant *Candida auris*: 'new kid on the block' in hospital-associated infections?** *J Hosp Infect*. 2016; 94(3): 209–12.
[PubMed Abstract](#) | [Publisher Full Text](#)
 48. Molepo JSE, Blignaut E: **Antifungal susceptibility of oral *Candida* isolates from HIV/AIDS patients.** *J Dent Res*. 2006; 85(Spec Issue B): 837.
 49. Wertheimer AI, Santella TM, Lauver HJ: **Successful public/private donation programs: a review of the diflucan partnership program in South Africa.** *J Int Assoc Physicians AIDS Care*. 2004; 3(3): 74–9, 84–5.
[PubMed Abstract](#) | [Publisher Full Text](#)
 50. Goldman M, Cloud GA, Smedema M, *et al.*: **Does long-term itraconazole prophylaxis result in *in vitro* azole resistance in mucosal *Candida albicans* isolates from persons with advanced human immunodeficiency virus infection? The National Institute of Allergy and Infectious Diseases Mycoses study group.** *Antimicrob Agents Chemother*. 2000; 44(6): 1585–7.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 51. Pelletier R, Peter J, Antin C, *et al.*: **Emergence of resistance of *Candida albicans* to clotrimazole in human immunodeficiency virus-infected children: *in vitro* and clinical correlations.** *J Clin Microbiol*. 2000; 38(4): 1563–8.
[PubMed Abstract](#) | [Free Full Text](#)
 52. Rautemaa R, Richardson M, Pfaller M, *et al.*: **Reduction of fluconazole susceptibility of *Candida albicans* in APECED patients due to long-term use of ketoconazole and miconazole.** *Scand J Infect Dis*. 2008; 40(11–12): 904–7.
[PubMed Abstract](#) | [Publisher Full Text](#)
 53. Makita K, Takahashi K, Karara A, *et al.*: **Experimental and/or genetically controlled alterations of the renal microsomal cytochrome P450 epoxigenase induce hypertension in rats fed a high salt diet.** *J Clin Invest*. 1994; 94(6): 2414–20.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 54. Kaplan JE, Benson C, Holmes KK, *et al.*: **Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America.** *MMWR Recomm Rep*. 2009; 58(RR-4): 1–207; quiz CE1-4.
[PubMed Abstract](#) | [Publisher Full Text](#)
 55. Pursley TJ, Blomquist IK, Abraham J, *et al.*: **Fluconazole-induced congenital anomalies in three infants.** *Clin Infect Dis*. 1996; 22(2): 336–40.
[PubMed Abstract](#) | [Publisher Full Text](#)
 56. Lopez-Rangel E, Van Allen MI: **Prenatal exposure to fluconazole: an identifiable dysmorphic phenotype.** *Birth Defects Res A Clin Mol Teratol*. 2005; 73(11): 919–23.
[PubMed Abstract](#) | [Publisher Full Text](#)
 57. Roemer T, Krysan DJ: **Antifungal drug development: challenges, unmet clinical needs, and new approaches.** *Cold Spring Harb Perspect Med*. 2014; 4(5): pii: a019703.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)

Open Peer Review

Current Peer Review Status:

Version 1

Reviewer Report 11 January 2017

<https://doi.org/10.5256/f1000research.11123.r19187>

© 2017 Ndip R. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Roland N. Ndip

Department of Microbiology and Parasitology, Faculty of Science, University of Buea, Buea, Cameroon

The title is appropriate for the content of the work; and the abstract captures a very good summary of the respective sections of the work. To me it is well written.

The content is excellently presented with a very good and balanced literature review. All the articles cited are not only current, but very relevant to the scope of the work. The gaps in knowledge in this area were well highlighted and a good attempt made to bridge the gap.

The conclusions are in line with the results obtained, and have profound recommendations which will improve on antifungal antimicrobial chemotherapy in sub-Saharan Africa.

However, I have some minor questions, which I think would improve on the presentation if addressed.

In the methods section under inclusion criteria: I was wondering why only studies conducted between 1998 and 2016 were used? Authors should state reasons to justify the stated period.

Except for journal instructions, I am of the opinion that merging Results and Discussion as a single section to read: Results/Discussion will be better since so much discussion has been taken under the results section.

Competing Interests: No competing interests were disclosed.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Reviewer Report 06 January 2017

<https://doi.org/10.5256/f1000research.11123.r18772>

© 2017 de Almeida A. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

António Paulo Gouveia de Almeida

¹ The Institute for Tropical Medicine, Universidade NOVA de Lisboa, Lisbon, Portugal

² Faculty of Health Sciences, University of Pretoria, Pretoria, South Africa

This is a very good and much needed review. The subject in question, *Candida* antifungal drug resistance in sub-Saharan Africa, is most pertinent and up to date.

I would, however, suggest that, similarly to what authors do in the Introduction, they would mention in Discussion, how is the situation of *Candida* antifungal drug resistance in sub-Saharan Africa different from that in the rest of the world, in a general outlook and as a result from this literature review.

Competing Interests: No competing interests were disclosed.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com

F1000Research